TY - JOUR
T1 - Lack of correlation between thiazide-induced hyperglycemia and hypokalemia
T2 - Subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study
AU - Smith, Steven M.
AU - Anderson, Shawn D.
AU - Wen, Sheron
AU - Gong, Yan
AU - Turner, Stephen T.
AU - Cooper-DeHoff, Rhonda M.
AU - Schwartz, Gary L.
AU - Bailey, Kent
AU - Chapman, Arlene
AU - Hall, Karen L.
AU - Feng, Hua
AU - Boerwinkle, Eric
AU - Johnson, Julie A.
AU - Gums, John G.
PY - 2009/10
Y1 - 2009/10
N2 - Study Objective. To determine whether changes in serum glucose, serum potassium, and plasma insulin levels are correlated in a cohort of hypertensive patients. Design. Prespecified subgroup analysis of results from a prospective, multicenter, randomized, open-label, parallel-group study. Setting. Primary care clinics at three tertiary care medical centers. Patients. Community-based ambulatory population of 202 patients (age range 17-65 yrs) with a new diagnosis of hypertension, untreated hypertension, or known hypertension, who were previously treated with fewer than three antihypertensive drugs and had no evidence of cardiovascular disease or diabetes mellitus. Intervention. Monotherapy with oral hydrochlorothiazide 12.5 or 25 mg/day for 9 weeks. Measurements and Main Results. Fasting serum glucose, serum potassium, and plasma insulin levels were obtained at baseline (before hydrochlorothiazide therapy was started) and after 9 weeks of therapy. Significant elevations were noted in fasting serum glucose (mean ± SD 3.42 ± 10.38 mg/dl, p<0.0001) and plasma insulin (2.35 ± 9.47 μIU/ml, p<0.0001) levels, and a significant reduction in serum potassium level (0.30 ± 0.44 mEq/L, p<0.0001) was noted. No significant correlation was observed between changes in fasting serum glucose and potassium levels (r = 0.022, 95% confidence interval (CI) -0.120-0.164, p=0.757) or between changes in serum potassium and plasma insulin levels (r = -0.112, 95% CI -0.256-0.037, p=0.140). Changes in serum glucose levels did not differ significantly between patients maintaining serum potassium levels of 4.0 mEq/L or greater and those with levels below 4.0 mEq/L. Conclusion. Changes in serum potassium and serum glucose levels were not correlated in individuals receiving hydrochlorothiazide monotherapy; thus maintenance of normal potassium levels may not attenuate the risk of thiazide diuretic-induced hyperglycemia.
AB - Study Objective. To determine whether changes in serum glucose, serum potassium, and plasma insulin levels are correlated in a cohort of hypertensive patients. Design. Prespecified subgroup analysis of results from a prospective, multicenter, randomized, open-label, parallel-group study. Setting. Primary care clinics at three tertiary care medical centers. Patients. Community-based ambulatory population of 202 patients (age range 17-65 yrs) with a new diagnosis of hypertension, untreated hypertension, or known hypertension, who were previously treated with fewer than three antihypertensive drugs and had no evidence of cardiovascular disease or diabetes mellitus. Intervention. Monotherapy with oral hydrochlorothiazide 12.5 or 25 mg/day for 9 weeks. Measurements and Main Results. Fasting serum glucose, serum potassium, and plasma insulin levels were obtained at baseline (before hydrochlorothiazide therapy was started) and after 9 weeks of therapy. Significant elevations were noted in fasting serum glucose (mean ± SD 3.42 ± 10.38 mg/dl, p<0.0001) and plasma insulin (2.35 ± 9.47 μIU/ml, p<0.0001) levels, and a significant reduction in serum potassium level (0.30 ± 0.44 mEq/L, p<0.0001) was noted. No significant correlation was observed between changes in fasting serum glucose and potassium levels (r = 0.022, 95% confidence interval (CI) -0.120-0.164, p=0.757) or between changes in serum potassium and plasma insulin levels (r = -0.112, 95% CI -0.256-0.037, p=0.140). Changes in serum glucose levels did not differ significantly between patients maintaining serum potassium levels of 4.0 mEq/L or greater and those with levels below 4.0 mEq/L. Conclusion. Changes in serum potassium and serum glucose levels were not correlated in individuals receiving hydrochlorothiazide monotherapy; thus maintenance of normal potassium levels may not attenuate the risk of thiazide diuretic-induced hyperglycemia.
KW - Hydrochlorothiazide
KW - Hyperglycemia
KW - Hypokalemia
KW - Thiazide diuretics
KW - Thiazide-induced hyperglycemia
UR - http://www.scopus.com/inward/record.url?scp=70349668312&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349668312&partnerID=8YFLogxK
U2 - 10.1592/phco.29.10.1157
DO - 10.1592/phco.29.10.1157
M3 - Article
C2 - 19792989
AN - SCOPUS:70349668312
SN - 0277-0008
VL - 29
SP - 1157
EP - 1165
JO - Pharmacotherapy
JF - Pharmacotherapy
IS - 10
ER -